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Acute Kidney Injury due to Menstruation-related Disseminated 
Intravascular Coagulation in an Adenomyosis Patient:  
A Case Report
The authors report a case of acute kidney injury (AKI) resulting from menstruation-related 
disseminated intravascular coagulation (DIC) in an adenomyosis patient. A 40-yr-old 
woman who had received gonadotropin for ovulation induction therapy presented with 
anuria and an elevated serum creatinine level. Her medical history showed primary 
infertility with diffuse adenomyosis. On admission, her pregnancy test was negative and 
her menstrual cycle had started 1 day previously. Laboratory data were consistent with DIC, 
and it was believed to be related to myometrial injury resulting from heavy intramyometrial 
menstrual flow. Gonadotropin is considered to play an important role in the development 
of fulminant DIC. This rare case suggests that physicians should be aware that gonadotropin 
may provoke fulminant DIC in women with adenomyosis.
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INTRODUCTION
Disseminated intravascular coagulation (DIC) is characterized 
by the systemic intravascular activation of coagulation (1). DIC 
can contribute to acute kidney injury (AKI) and other multior-
gan failures due to the widespread deposition of fibrin in the 
circulation and the consequent compromise of blood supply to 
various organs. DIC is associated with various gyneco-obstetric 
conditions, such as, uterine leiomyoma and abruptio placenta. 
However, DIC associated with adenomyosis is uncommon. A 
literature review revealed only one report of DIC development 
during menstruation in an adenomyosis patient (2). However, 
in this previously reported case, AKI and other organ failures 
were not observed.
  We here present a case of AKI which resulting from menstru-
ation-related DIC that was probably provoked by gonadotropin 
administration.
 
CASE REPORT
A 40-yr-old woman who had experience of primary infertility 
with diffuse adenomyosis (Fig. 1) presented with anuria and an 
elevated serum creatinine (SCr) level at the Emergency Medi-
cine Department on May 28, 2008. She had a history of two cycles 
of in vitro fertilization (IVF) at an infertility clinic, and the second 
cycle was performed 3 weeks prior to admission. Each cycle of 
IVF was treated with long protocol of gonadotropin-releasing 
hormone (GnRH) agonist. For ovulation induction, daily 500 IU 
of human menopausal gonadotropin was administered on men-
strual cycle days 3-15 and 5,000 IU of human chorionic gonad-
otropin (hCG) was administered on day 16, at 18 mm of leading 
follicles size. Ovum aspiration was performed at 36 hr after hCG 
injection. Five and nine oocytes were obtained at first and sec-
ond cycle, respectively. Daily 50 mg of progesterone and once 
every three days 1,000 IU of hCG were administered for luteal 
support. The objective evidences of ovarian hyperstimulation 
syndrome were not present on the day of ovum collection and 
7 days later. 
  On admission, her blood urea nitrogen (BUN) level was 41.1 
mg/dL, and her SCr level was 3.5 md/dL. An examination of 
medical records revealed a baseline SCr level of 0.8 mg/dL, and 
a physical examination revealed an extremely enlarged uterus, Son J, et al.  •  Menstruation-related Disseminated Intravascular Coagulation 
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which was palpable at the level of the umbilicus. Her pregnancy 
test was negative and her menstrual cycle had started 1 day be-
fore admission. Her vital signs were stable, and renal ultraso-
nography excluded an acute ureteral obstruction.
  Laboratory testing showed the following: white blood cell 
(WBC) count 30.07×10
9/L, hemoglobin level (Hb) 10.0 g/dL, 
hematocrit (Hct) 29.6%, platelet count 39×10
9/L, lactate dehy-
drogenase (LDH) 7,914 IU/L, aspartate aminotransferase (AST) 
329 IU/L, alanine aminotransferase (ALT) 92 IU/L, alkaline phos-
phatase (ALP) 180 IU/L, total bilirubin 2.72 mg/dL, and cancer 
antigen 125 (CA125) 16,684 U/mL. A peripheral blood smear 
revealed numerous schistocytes.
  A coagulation test revealed the characteristics of DIC (1). Her 
laboratory values were as follows: prothrombin time (PT) 24.6 
sec (normally 11.0 to 14.1 sec), prothrombin time-internation-
alized ratio (PT-INR) 2.25, activated partial thromboplastin time 
(aPTT) 58.2 sec (normally 30 to 44 sec), fibrinogen level 88 mg/
dL, D-dimer level 19.3 μg/mL, and antithrombin III level 74%. 
She had no known factor predisposing DIC, such as, infection 
or a malignancy.
  Urinalysis revealed numerous red and white blood cells, but 
her urine and blood cultures were negative. Serologies for anti-
nuclear antibodies (ANA), antineutrophil cytoplasmic antibod-
ies (ANCA), cryoglobulins, hepatitis B surface antigen (HBsAg), 
anti-glomerular basement membrane antibodies (Anti-GBM), 
and antistreptococcal antibodies were all negative. Complement 
levels were within the normal range. Furthermore, both serum 
and urine protein electrophoresis failed to demonstrate a mono-
clonal component, and her computed tomographic renal scan 
was unremarkable. 
  Under a diagnosis of AKI resulting from unexplained DIC, the 
patient was treated with 0.9% sodium chloride solution, fresh 
frozen plasma, and platelet concentrates. However, despite treat-
ment, the patient required continuous renal replacement ther-
apy and therapeutic plasmapheresis due to progressive AKI and 
multiorgan failures. The menstrual phase was terminated on the 
fourth hospital day, and coagulation test findings then gradual-
ly improved. Her SCr level peaked on the 14th hospital day, and 
reached a nadir of 1.1 mg/dL on 30th hospital day. The patient 
was treated with GnRH agonist for 3 months, and then under-
went hysterectomy on September 28, 2008. Pathological find-
ings confirmed diffuse adenomyosis (Fig. 2).
DISCUSSION
Adenomyosis is a benign gynecological condition that is char-
acterized by the presence of endometrial glands and stroma 
within the myometrium (3). In adenomyosis patients, AKI is 
usually caused by obstructive uropathy. Furthermore, an uterus 
affected by adenomyosis can enlarge to that expected on the 
12th gestational week. In addition, adenomyosis is frequently 
associated with other uterine conditions, such as, leiomyoma 
(35-55%) or pelvic endometriosis (5-20%). Thus, the differential 
diagnosis of AKI should include obstructive uropathy, either 
caused by adenomyosis per se or by coexisting conditions, such 
as, a bulky leiomyoma or ureteral endometriosis.
  In our case, renal ultrasonography excluded obstructive urop-
athy and laboratory data were consistent with AKI resulting from 
unexplained DIC. Accordingly, because she had no known fac-
tor predisposing DIC, menstruation-related DIC was suspect-
ed. Nakamura et al. reported the first case of DIC development 
Fig. 1. T2-weighted MRI scan showing extensive adenomyosis involvement. Low 
signal intensity areas involving most of the uterus demonstrated diffuse thickening of 
the junctional zone. Punctuate high signal foci represent islands of ectopic endometrial 
tissue or microhemorrhage (arrows).
Fig. 2. Pathological findings of hysterectomized uterus. (A) Gross appearance of ade-
nomyosis. Note coarsely trabeculated, diffusely hypertrophied myometrium stippled 
with foci of ectopic endometrium. (B) Hematoxylin and eosin-stained section of uterus, 
showing endometrial glands and stroma surround  ed by hypertrophied myometrium. 
Occasional hemosiderin-laden macrophages were also observed. Magnification, ×100. 
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during menstruation in an adenomyosis patient, and proposed 
a myometrial injury mechanism (2). We agree that myometrial 
injury resulting from heavy intramyometrial menstrual flow 
might activate the tissue factor coagulation pathway. However, 
fulminant DIC with AKI and other organ failures was not ob-
served in their case.
  We believe that gonadotropin played an important role in the 
development of fulminant DIC in our patient. Adenomyosis is 
often accompanied by adjacent myometrial smooth muscle 
hyperplasia, and adenomyotic tissue and myometrium are 
known to express estrogen and progesterone receptors (4, 5). 
Therefore, gonadotropin, which stimulates ovarian steroido-
genesis, can promote the proliferation of adenomyotic tissue 
and adjacent myometrium, and thus, contribute to extensive 
myometrial injury during menstruation.
  In addition, gonadotropin can provoke fulminant DIC via 
another mechanism. The myometrium is a significant source of 
tissue factor, which plays a key role in the initiation of coagula-
tion (6). Furthermore, because tissue factor expression is also 
under the control of ovarian steroids (7), gonadotropin might 
contribute to the overexpression of tissue factor and activation 
of the coagulation cascade.
  Adenomyosis can be confirmed only by pathologic examina-
tions of hysterectomy specimens. However, recent studies have 
shown that MRI can accurately diagnose adenomyosis, and that 
it has a sensitivity and specificity that range from 86 to 100% (8). 
Furthermore, it appears that non-enhanced T2-weighted imag-
ing is useful in the setting of AKI because of the risk of nephro-
genic systemic fibrosis.
  Like endometriosis, adenomyosis is a hormone-sensitive dis-
ease (9). Moreover, because the growth of adenomyotic tissue is 
associated with a hyperestrogenic state, hormonal therapy based 
on progesterones, oral contraceptive pills, anti-estrogens, or GnRH 
agonists could be useful. Our patient did not experience recur-
rent DIC after GnRH agonist treatment, which creates a hypoes-
trogenic environment. Thus, hormonal therapy might prevent 
further DIC aggravation, especially when hysterectomy is con-
traindicated in patients with multiple organ failures.
  Adenomyosis is a common disorder that present in 20-35% 
of women undergoing hysterectomy for benign gynecological 
disorders. Presenting symptoms include an enlarged uterus, 
menorrhagia, and dysmenorrhea. Infertility is a less frequent 
complaint because the majority of cases are diagnosed in their 
fourth and fifth decades of life. However, because an increasing 
number of women now postpone their first pregnancy until the 
late thirties, adenomyosis is being encountered more frequent-
ly in infertility clinics (10).
  Summarizing, we experienced a case of adenomyosis in a 40- 
yr-old woman who developed AKI due to menstruation-related 
DIC development after gonadotropin administration. Physicians 
should be aware that gonadotropin can provoke fulminant DIC 
in women with adenomyosis.
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